Premium
Coronary stenting in stable patients: Identification of a low‐risk subgroup that may not require adjunctive antiplatelet therapy
Author(s) -
Mann Tift,
Cubeddu Roberto J.,
Raynor Laura,
Bowen Josie,
Schneider Joel E.,
Rose Gregory,
Cubeddu Gabriela,
Ali Raza Jaffar,
Jobe Robert Lee,
Newman William,
Zellinger Micheal
Publication year - 2003
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10479
Subject(s) - medicine , mace , abciximab , coronary stenting , myocardial infarction , clopidogrel , adjunctive treatment , percutaneous coronary intervention , cardiology , randomized controlled trial , diabetes mellitus , subgroup analysis , surgery , stent , meta analysis , restenosis , endocrinology
The present study prospectively evaluated adjunctive antiplatelet therapy in patients without insulin‐requiring diabetes during elective coronary stenting. Three hundred patients were randomized to one of three treatment groups: clopidogrel pretreatment, adjunctive abciximab, or control. Stenting was successful in 98% and no deaths occurred. Thirty‐day and 1‐year major adverse coronary events (MACEs) was similar in all groups. A subgroup of 109 patients undergoing single‐vessel stenting of type A/B1 lesions with short guidewire times had no postprocedure myocardial infarction or 30‐day MACE. We conclude that patients with these characteristics may safely undergo elective coronary stenting without adjunctive antiplatelet therapy. Cathet Cardiovasc Intervent 2003;58: 459–466. © 2003 Wiley‐Liss, Inc.